Lumida
/AMBQ
⌘K
AMBQ

AMBQ

AMBQ
$63.52USD+4.71%+2.86 today

MARKET CAP

1.5B

P/E (TTM)

FWD P/E

DAY RANGE

$61 – $64

52W RANGE

$22
$92

AI Summary

Stalk
StalkMedium

AMBQ is in a mean-reversion pivot with price repairing above short-term EMAs, signaling potential structural repair. However, resistance at the 50-day SMA limits near-term upside. Medium-term directional asymmetry favors bullish entries, but price is currently extended above the 9-/20-EMA cluster. A retracement and reclamation of these EMAs near support would offer a disciplined entry. Failure to reclaim the 50-day SMA or a reversal below the 20-day EMA would invalidate this bias.

  • Q2 revenue +89.7% YoY to $33.9M, beating estimates
  • Non-GAAP gross margin at 47.2% yielded $16M gross profit
  • Q2 net loss of $7.1M underscores unprofitable operations
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Ambiq Micro (NASDAQ: AMBQ) is an emerging player in the semiconductor industry, specializing in ultra-low power solutions for edge AI applications. The company has established itself as a key innovator with its proprietary SPOT technology, providing significant advantages in performance and efficiency. Positioned within the growing demand for edge computing and AI, Ambiq is well-placed to benefit from the increasing global emphasis on energy-efficient processing solutions.

Bull says

  • Q2 revenue +89.7% YoY to $33.9M, beating estimates
  • Non-GAAP gross margin at 47.2% yielded $16M gross profit
  • heliaPROFILER and Apollo line upgrades drive edge AI demand
  • Full-year 2026 net sales guidance of $135M supports growth
  • Upsized public offering secures cash runway for expansion
  • Strong momentum and liquidity factors underpin market interest

Bear says

  • Q2 net loss of $7.1M underscores unprofitable operations
  • Weak profitability factors and cash burn challenge break-even timing
  • High volatility factors suggest significant share price swings
  • Low institutional ownership and $16.3M insider selling hurt sentiment
  • Negative earnings yield factors point to overvaluation risk
  • Supply constraints and balance sheet weakness may hamper growth

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-11-2026neutral

Transcript signals

Read full transcript analysis ›